Secondary Parkinson Disease

Secondary Parkinson disease refers to a group of disorders that present similarly to Parkinson disease but have different etiology. Secondary Parkinson disease is caused due to the blockade of or interference in dopamine’s action in the basal ganglia. Here is the latest research.

December 18, 2020

Defective Somatosensory Inhibition and Plasticity Are Not Required to Develop Dystonia

Movement Disorders : Official Journal of the Movement Disorder Society
Anna LatorreLorenzo Rocchi
August 30, 2020
Case Report

Neurological Symptoms of Congenital Portosystemic Shunt Reversed by Venous Endovascular Intervention: A Six Years Follow-Up Study

Neurology India
Federico Martin RioloJosé Antonio Díaz
October 10, 2020
Open Access

Pregabalin-associated movement disorders: A literature review

Brain Circulation
Jamir Pitton Rissardo, Ana Leticia Fornari Caprara
September 5, 2020
Open Access

Drug-Induced Movement Disorders and Its Associated Factors Among Patients Attending Treatment at Public Hospitals in Eastern Ethiopia

Neuropsychiatric Disease and Treatment
Tadesse MisganaGetachew Asfaw
December 1, 2020

Thalamic deep brain stimulation for acquired dystonia in children and young adults: a phase 1 clinical trial

Journal of Neurosurgery. Pediatrics
Marta San LucianoJill L Ostrem
December 29, 2020

Tiron alleviates MPTP-induced Parkinsonism in mice via activation of Keap-1/Nrf2 pathway

Journal of Biochemical and Molecular Toxicology
Shrook A MohamedManar A Nader
December 29, 2020

A Real-World Study of Cerebral 99mTc-TRODAT-1 Single-Photon Emission Computed Tomography (SPECT) Imaging of the Dopamine Transporter in Patients with Parkinson Disease from a Tertiary Hospital in Brazil

Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
Michelly ArjonaAndre C Felicio
July 14, 2020
Open Access

From encephalitis lethargica to COVID-19: Is there another epidemic ahead?

Clinical Neurology and Neurosurgery
Rahim Badrfam, Atefeh Zandifar
October 22, 2020
Open Access

Neuroprotective effects of Shende’an tablet in the Parkinson’s disease model

Yan Xiao ShengSai Li
July 30, 2020

Revisiting amantadine as a treatment for drug-induced movement disorders

Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists
Stanley N CaroffJames F Morley
October 7, 2020

Predicting Early Stage Drug Induced Parkinsonism using Unsupervised and Supervised Machine Learning

Annual International Conference of the IEEE Engineering in Medicine and Biology Society
Parvathy NairHoam Chung
November 13, 2020
Open Access

Clinical Spectrum of Drug-Induced Movement Disorders: A Study of 97 Patients

Tremor and Other Hyperkinetic Movements
Anjali Chouksey, Sanjay Pandey
September 13, 2020
Open Access

Roles of lysosomotropic agents on LRRK2 activation and Rab10 phosphorylation

Neurobiology of Disease
Tomoki KuwaharaTakeshi Iwatsubo
September 29, 2020

Non-invasive brain stimulation targets and approaches to modulate gambling-related decisions: A systematic review

Addictive Behaviors
Mauro PettorrusoMassimo di Giannantonio
December 15, 2020

Incidental Finding of Bilateral Thalamic Glioma on 99mTc TRODAT-1 SPECT/CT

Clinical Nuclear Medicine
Ni-Chun KuoHung-Pin Chan

Sign up to follow this feed and discover related papers.

Related Feeds

3D Cellular Models of Brain and Neurodegeneration

Brain organoids are three-dimensional in vitro cellular models of the brain that can recapitulate many processes such as the neurodevelopment. In addition, these organoids can be combined with other cell types, such as neurons and astrocytes to study their interactions in assembloids. Disease processes can also be modeled by induced pluripotent stem cell-derived organoids and assembloids from patients with neurodegenerative disorders. Discover the latest research on the models here.


TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

Alexander Disease

Alexander disease is a rare leukodystrophy caused by mutations in the astrocyte-specific intermediate filament protein glial fibrillary acidic protein (GFAP). Here is the latest research on this disease.

© 2021 Meta ULC. All rights reserved